Rare diseases, affecting over 300 million people globally, have long been neglected by traditional healthcare models. However, personalized medicine is changing this, offering tailored therapies for patients with unique genetic profiles that don’t respond to mass-produced drugs. With the FDA approving over 50 orphan drugs annually and the EU’s Orphan Drug Regulation incentivizing...